Combination immunotherapy for melanoma yields decade-long survival rates
The 10-year follow-up study involved 945 patients across 137 sites in 21 countries Roughly half of metastatic melanoma patients treated with a combination of immune checkpoint inhibitors remain cancer-free for a decade, according to a new report from Weill Cornell Medicine and Dana-Farber Cancer Center investigators and their colleagues, published in the New England […]